Extending Dabrafenib + Trametinib Beneficial in Stage III Melanoma

Extending adjuvant dabrafenib + trametinib beyond one year linked to better relapse-free survival
skin cancer surgery mohs melanoma
Adobe Stock
Published on: 
Updated on: 
Loading content, please wait...

Related Stories

No stories found.
logo
www.healthday.com